



November 11, 2025

<b>To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497</b>	<b>To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL</b>
--	---

**Sub: Outcome of Board Meeting held on November 11, 2025 of ANLON HEALTHCARE LIMITED – Financial Results for the quarter and half year ended September 30, 2025.**

Respected Sir/Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of Board Meeting of the Company held on Tuesday, November 11, 2025 at the Registered Office of the Company and the following matters inter alia have been considered, approved and taken on record by the Board of Directors:

- i) Standalone Unaudited Financial Results for the quarter and Half year ended on September 30, 2025 and Auditor's Report thereon, attached herewith.
- ii) Disclosure on Related Party Transaction as per Regulation 23 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, attached herewith.
- iii) Disclosure on Statement of Deviation and Variation of Fund raised as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, attached herewith.

Meeting Commenced on 01:30 p.m. IST and Concluded on 02:30 p.m. IST.

You are requested to take the above information on your record.

Thanking You.

**For ANLON HEALTHCARE LIMITED**

**PUNITKUMAR RASADIA  
MANAGING DIRECTOR  
DIN: 06696258**

---

**ANLON HEALTHCARE LIMITED**

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: [info@anlonhealthcare.com](mailto:info@anlonhealthcare.com) | [www.anlon.in](http://www.anlon.in)




**Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Anlon Healthcare Limited**

- (1) We have reviewed the accompanying statement of unaudited standalone financial results of Anlon Healthcare Limited (the 'Company') for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
- (2) This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- (3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- (4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No 143936W

Date: 11/11/2025  
Place: Rajkot

  
Kaushal V. Dave  
(Partner)  
Membership No 174550  
UDIN: 25174550BMLN MU3148



**R V D & Co**

**Chartered Accountants**

**"Level-06", Office No 604-605, Near AP Park, Opp Imperial Heights, Rajkot-360005**

Anlon Healthcare Limited

CIN: U24230GJ2013PLC077543

Address: 101/102 - Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005

Standalone Balance Sheet as at 30-09-2025

Rs. in Lacs

Particulars	Half Year ended	Year Ended
	30-09-2025	31 March 2025
	Un Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	2,196.92	2,281.90
<b>Total Non-current Assets</b>	2,196.92	2,281.90
<b>Current assets</b>		
Inventories	5,653.12	5,026.31
Financial Assets		
Investments	1,834.09	90.91
Trade receivables	10,745.14	7,499.87
Cash and cash equivalents	2,494.07	144.96
Loans	236.84	227.95
Other financial assets	1,831.00	138.04
Other current assets	5,956.66	2,720.05
<b>Total Current Assets</b>	28,750.92	15,848.09
<b>Total Assets</b>	<b>30,947.84</b>	<b>18,129.99</b>
<b>II. EQUITY and LIABILITIES</b>		
Equity Share Capital	5,315.15	3,985.15
Other Equity	16,116.44	4,057.02
<b>Total Equity</b>	21,431.59	8,042.17
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	3,085.83	3,835.70
Provisions	24.40	24.40
Deferred tax liabilities net	217.41	222.50
<b>Total Non-current liabilities</b>	3,327.64	4,082.60
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	2,696.68	1,999.04
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	133.90	47.68
- total outstanding dues of others	1,521.92	1,916.67
Other current liabilities	511.49	1,178.05
Provisions - current	1,324.62	863.78
<b>Total Current liabilities</b>	6,188.61	6,005.22
<b>Total liabilities</b>	9,516.25	10,087.82
<b>Total Equity and Liabilities</b>	<b>30,947.84</b>	<b>18,129.99</b>

For and on behalf of Board of Directors,

Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543)

Date: November 11, 2025

Place: Rajkot

  
Punit Kumar R. Rasadia  
Managing Director 6696258



  
Meet A. Vachhani  
Whole Time Director 6695053

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 11/11/2025

Place: Rajkot

**Anlon Healthcare Limited**

CIN: U24230GJ2013PLC077543

Address: 101/102 - Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005

Standalone Financial Result for the period ended on 30-09-2025

Sr No	Particulars	Quarter Ended		Half year ended		Year Ended	
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	<b>Income</b>						
	Revenue From Operations	5,220.13	3,329.72	2,416.63	8,549.85	6,199.88	12,028.66
	Other Income	2.72	1.17	4.64	3.89	10.73	16.85
	<b>Total Income (I)</b>	<b>5,222.85</b>	<b>3,330.89</b>	<b>2,421.27</b>	<b>8,553.74</b>	<b>6,210.61</b>	<b>12,045.51</b>
II	<b>Expenses</b>						
	Cost of materials consumed	4,082.98	2,959.48	1,850.56	7,042.46	3,799.66	7,128.82
	Changes in inventories of finished goods, Stock-in -Trade and work-	-787.16	-537.19	-491.85	-1,324.35	331.87	329.89
	Employee benefits expense	106.17	122.49	124.70	228.66	241.11	488.19
	Finance costs	86.61	81.71	93.05	168.32	191.44	371.52
	Depreciation and amortization expense	45.21	42.68	47.29	87.89	94.58	177.39
	Other expenses	444.36	161.31	181.03	605.67	382.95	860.88
	<b>Total expenses (II)</b>	<b>3,978.17</b>	<b>2,830.48</b>	<b>1,804.78</b>	<b>6,808.65</b>	<b>5,041.61</b>	<b>9,356.69</b>
III	<b>Profit/(loss) before tax (I-II)</b>	<b>1,244.68</b>	<b>500.41</b>	<b>616.49</b>	<b>1,745.09</b>	<b>1,169.00</b>	<b>2,688.82</b>
IV	<b>Tax expense</b>						
	Current tax	315.85	147.91	300.60	463.76	386.92	757.20
	Deferred tax	-2.90	-2.19	-2.04	-5.09	-4.01	-17.46
	MAT Credit Entitlement	-	-	58.70	-	150.51	-102.71
	<b>Total Tax expense (IV)</b>	<b>312.95</b>	<b>145.72</b>	<b>357.26</b>	<b>458.67</b>	<b>533.42</b>	<b>637.03</b>
V	<b>Profit/(loss) after tax for the period (III-IV)</b>	<b>931.73</b>	<b>354.69</b>	<b>259.23</b>	<b>1,286.42</b>	<b>635.58</b>	<b>2,051.79</b>
VI	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to profit or loss						
	Items that will be reclassified to profit or loss						
	<b>Total Other Comprehensive Income (VI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
VII	<b>Total Comprehensive Income for the period (V+VI)</b>	<b>931.73</b>	<b>354.69</b>	<b>259.23</b>	<b>1,286.42</b>	<b>635.58</b>	<b>2,051.79</b>
VIII	<b>Earnings per equity share</b>						
	Basic	2.22	0.89	0.41	3.07	2.56	6.37
	Diluted	2.22	0.89	0.41	3.07	2.56	6.37

Rs. in Lacs

Date: November 11, 2025  
Place: Rajkot

For and on behalf of Board of Directors,  
Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543)

  
Punitkumar R. Rasadia  
Managing Director 6696258

  
Meet A. Vachhani  
Whole Time Director 6695053

SIGNED FOR IDENTIFICATION BY  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 11/11/2025  
Place: Rajkot

**Anlon Healthcare Limited**

CIN: U24230GJ2013PLC077543


Registered office: 101/102 - Silvercoin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005

Standalone Cash Flow Statement for the period ended on 30-09-2025

Particulars	Rs. in Lacs	
	For Period ended 30 September 2025	For Period ended 31 March 2025
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit for the year	1,286.42	2,688.82
<b>Adjustments for:</b>		
Depreciation and amortisation	87.89	177.39
Interest Income	-	-8.12
Provision for Gratuity	-	2.35
Provision for CSR	-	30.46
Provision for Income tax	458.66	-
Finance Cost	168.32	371.52
<b>Operating profit before working capital changes</b>	<b>2,001.29</b>	<b>3,262.42</b>
<b>Adjustment for (increase) / decrease in operating assets</b>		
Trade receivables	-3,245.27	-3,626.82
Loans & Advances	-8.88	13.80
Other financial assets	-1,692.96	-82.23
Inventories	-626.81	-854.96
Other current assets	-3,236.60	-1,207.30
<b>Adjustment for (Increase) / decrease in operating liabilities</b>		
Trade payables	-308.54	-34.88
Employee benefit obligation	-	-
Other current Liabilities	-666.56	415.98
Provisions	460.84	-38.68
<b>Cash generated from operations</b>	<b>-7,323.49</b>	<b>-2,152.67</b>
Income tax paid (net)	-463.76	-102.50
<b>Net cash generated by operating activities</b>	<b>-7,787.25</b>	<b>-2,255.17</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	-2.92	-52.93
Purchase of other Investment	-1,743.17	-
Proceeds from disposal of property, plant and equipment	-	323.34
Interest received	-	8.12
<b>Net cash (used in) / generated by investing activities</b>	<b>-1,746.09</b>	<b>278.53</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from short term borrowings(Net)	697.63	-32.76
Proceeds from long term borrowings(Net)	-749.86	-1,588.82
Finance cost	-168.32	-371.52
Issue of Equity Shares	1,330.00	2,385.15
Other Equity	10,773.00	1,502.09
<b>Net cash used in financing activities</b>	<b>11,882.45</b>	<b>1,894.14</b>
Net increase / (decrease) in cash and cash equivalents	2,349.11	-82.50
Cash and cash equivalents at the beginning of the year	144.96	227.45
Exchange gain loss on Cash and cash equivalents	-	-
<b>Cash and cash equivalents at the end of the year</b>	<b>2,494.07</b>	<b>144.95</b>

Particulars	For Period ended 30 September 2025	For Period ended 31 March 2025
Reconciliation of Cash and Cash Equivalents with Balance Sheet:		
Cash and cash equivalents includes		
Cash on hand	228.01	144.09
Balances with Banks	2,266.06	0.85

For and on behalf of Board of Directors,  
Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543)

  
**Punitkumar R. Rasad Meet A. Vachhani**  
Managing Director 669/ Whole Time Director 6695053

Date November 11, 2025  
Place Rajkot

**SIGNED FOR IDENTIFICATION BY**  
R V D & Co.  
Chartered Accountants  
FRN 143936W

Date: 11/11/2025  
Place: Rajkot

## Anlon Healthcare Limited

CIN: U24230GJ2013PLC077543

### Notes to the Standalone Financial Result for the period ended on 30-09-2025

#### 1 Corporate information

Anlon Healthcare Limited ("the Company") is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The Company is based in Rajkot, India, and has earned global recognition for manufacturing high-quality pharmaceutical bulk drugs that adhere to stringent international standards.

Anlon Healthcare Limited is a publicly listed company in India. The equity shares of the Company are listed on the National Stock Exchange of India Limited (NSE) under the symbol "AHCL" and on the BSE Limited (Bombay Stock Exchange) under the code 544497. The Company was listed on both exchanges on September 3, 2025.

#### 2 Basis of Preparation

The Financial Statements of the Company have been prepared to comply with the Indian Accounting standards ('Ind AS'), including the Rules notified under the relevant provisions of the Companies Act, 2013, (as amended from time to time) and Presentation and disclosure requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS Compliant Schedule III) as amended from time to time. The Company follows indirect method prescribed in Ind AS 7 – Statement of Cash Flows for presentation of its cash flows.

The standalone financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities which have been measured at fair value (refer accounting policy regarding financial instruments) and derivative financial instruments.

The standalone financial statements are presented in Indian Rupees (₹) and all values are rounded to the nearest lakh (₹00,000), except when otherwise indicated. Further All assets and liabilities have been classified as current and non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Act and Ind AS 1 - Presentation of Financial Statements.

#### 3 Segment Reporting

Anlon Healthcare Limited is primarily engaged in the business of manufacturing and sale of Active Pharmaceutical Ingredients (APIs). The entire operations of the Company are managed and reviewed by the management as one integrated business segment. Accordingly, based on the "management approach" prescribed under Ind AS 108 – Operating Segments, the Company has determined that segment reporting is not applicable to its operations.

#### 4 The Status of investor complaints received by the company is as follows :

Number of Investor Complaints carried forward from the quarter ended 30.06.2025	NIL	
Number of Investor Complaints received for the period 01.07.2025 – 30.09.2025		2
Number of Investor Complaints resolved during the quarter 01.07.2025 – 30.09.2025		1
Number of Investor Complaints lying unresolved for the quarter ended 30.09.2025		1

#### Type of Complaints: -

Share related	-	
Dividend related	-	
Annual reports related	-	
MISC – Others /Application money/Refund/IPO		2

#### 5 List of Group Companies or Subsidiary company


Nil

6 The above financial results of Anlon Healthcare Limited (the "Company") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on November 11, 2025 and November 11, 2025, respectively

7 The figures for the previous year have been re-grouped, re-classified, and re-arranged wherever necessary to conform to the current year's presentation and classification. Such re-grouping or re-arrangement has been carried out to facilitate a more appropriate comparison with the current year's financial statements.

8 Other Expenses includes operational, statutory, and administrative expenses Power Fuel,Packing Material,Factory Electricity Expenses,Freight Inward,Advertisement Expenses,Canteen and -Import Duty Expenses Etc

For and on behalf of Board of Directors,  
Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543)



Punitkumar R. Rasadia  
Managing Director 6696258

Date November 11,2025

Place Rajkot



To,

**The Board of Directors**

**Anlon Healthcare Limited**

**101/102-Silver Coin Complex,**

**Opp. Crystal Mall, Kalawad Road,**

**Rajkot 360005, Gujarat (INDIA).**

**Sub: Statutory auditor's certificate in respect of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.**

**Dear Sir,**

1. This certificate is issued in accordance with a request received from Anlon Healthcare Limited (the 'Company').
2. The Company was listed on National Stock Exchange of India Ltd & Bombay Stock Exchange on September 03,2025. Pursuant to this initial public offer, the Company is required to submit a certificate with respect to utilization of the proceeds and indicate deviations, if any, from the objects stated in the offer document. Accordingly, We, R V D & Co., Chartered Accountants, the statutory auditors have been requested by the Company to verify the accompanying statement ('Annexure I') in respect of utilization of the funds for its intended purpose.
3. A copy of the accompanying statement has been attached.

**Management's responsibility**

4. The preparation of Annexure I is the responsibility of the management of the Company.
5. The preparation of the assertions for this certificate is the responsibility of the Management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the assertions for this certificate and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

**Our Responsibility**

6. Our responsibility is to give a limited assurance as to whether there is any deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30,2025 filed with the Securities and Exchange Board of India ("Prospectus").
7. We have examined the Annexure I prepared by the Company on a test check basis and initialed it for identification purposes only.
8. We have conducted our verification and issued this certificate in accordance with the Guidance Note on Reports or Certificates for Special Purposes to the extent applicable (the "Guidance Note") issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, "Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and other Assurance and Related Services Engagements" as revised from time to time.



**R V D & Co**

**Chartered Accountants**

**"Level-06,Office No 604-605,Near AP Park, Opp Imperial Heights,Rajkot-360005**



10. We have performed the following procedures in relation to this certificate:

1. Obtained the Prospectus dated August 30,2025 filed with the Securities and Exchange Board of India
2. Reviewed Board and auditing committee meeting minutes relating to utilisation of IPO proceeds and unutilized IPO funds
3. Obtained the unaudited books of accounts for the quarter and half year ended September 30, 2025
4. Obtained necessary records and documentation to verify Annexure I
5. Obtained necessary representations from the Management of the Company.

#### Conclusion

11 Based on the examination and procedures performed by us as stated above and according to the representation, information and explanation given to us by the management, we certify that the proceeds have been utilized for the intended purposes and there is no deviation in the utilization of the proceeds from the objects stated in the Prospectus dated August 30,2025 filed with the Securities and Exchange Board of India.

#### Restriction on use

(iii) The certificate has been issued at the request of the Company, for submission to the National Stock Exchange and Bombay Stock Exchange pursuant to the requirements of regulation under Chapter IV Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

For, R V D & Co  
Chartered Accountants  
ICAI Firm Registration No 143936W

Kaushal V.Dave  
(Partner)  
Membership No 174550  
UDIN: 25174550BMLNMT8047



Date: November 11,2025  
Place:Rajkot



**Annexure –I Statement of Deviation/Variation in utilisation of funds raised**

<b>Name of Listed Entity</b>	Anlon Healthcare Limited
<b>Mode of Fund Raising</b>	Public Issue / Right Issue / Preferential Issue / QIP / Others
<b>Date of Raising Funds</b>	Issue Opened on: August 26, 2025 Issue Closed on: August 29, 2025
<b>Amount Raised (In Rs.)</b>	Rs.12,103.00 Lacs
<b>Report filed for Quarter/ Half Year ended</b>	September 30, 2025
<b>Monitoring Agency</b>	Yes
<b>Monitoring Agency Name, if applicable</b>	Crisil Ratings Limited
<b>Is there a Deviation/Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation/ Variation</b>	Not Applicable
<b>Comments of the Audit Committee after review</b>	No Comment
<b>Comments of the Auditors, if any</b>	No Comment





Object(S)	Amount as per final offer document	Amount utilised at the beginning of the reported quarter	Amount utilised during the reported quarter	Amount utilised at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter	Reason for idle funds	Proposed course of actions
Funding capital expenditure requirements for the expansion of our Manufacturing Facility	3,071.95	-	634.99	634.99	2,436.96		
Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company	500.00	-	500.00	500.00	-		
Funding the Working capital requirement	4,315.00	-	4,315.00	4,315.00	-		
Offer Expense	1,513.05		1,416.86	1,416.86	96.19		
General corporate purposes	2,703.00	-	1,378.60	1,378.60	1,324.40		
<b>Total</b>	<b>12,103.00</b>	<b>-</b>	<b>8,245.45</b>	<b>8,245.45</b>	<b>3,857.55</b>		



# Anlon Healthcare Limited


CIN : U24230GJ2013PLC077543

101-102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat

Statement of Related Party Transaction as on 30.09.2025

												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken							
Details of Party (Listed Entity) Entering Into Transaction			Details of Counter party			Type of Related Party Transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee (Rs. In Lacs)	value of transaction during Period (Rs. In Lacs)	In case money are dues (Rs. In Lacs)		In case any financial indebtedness is incurred to make or give loans, interoperate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
Sr No.	Name	Pan	Name	Pan	Relationship of Counterparty with the listed entity Or its subsidiary				Opening Balance	Closing Balance	Nature of indebtedness (Loan/ Issuance of debt/ any other Debt etc.)	Cost	tenure	(Loans / Advance / Inter Corporate)	interest rate	Tenure	Secured / Unsecured	Purpose for which funds will be utilized by Ultimate Receipt of Funds	
1	Anlon Healthcare Limited	AAMCA1673J	ANLON CHEMICAL RESEARCH ORGANIZAITON	AARFA2209C	Promoter Group	Advance for Purchase	KMP Interested	183.02	183.02	-	183.02	-	-	-	-	-	-	-	-
2	Anlon Healthcare Limited	AAMCA1673J	ANLON CHEMICAL RESEARCH ORGANIZAITON	AARFA2209C	Promoter Group	Trade Receivable	KMP Interested	-	-	20.27	-	-	-	-	-	-	-	-	-
3	Anlon Healthcare Limited	AAMCA1673J	Anlon Lifescience Private Limited	AAPCA0663H	Promoter Group	Material Purchase	KMP Interested	700.16	700.16	-	-	-	-	-	-	-	-	-	-
4	Anlon Healthcare Limited	AAMCA1673J	Anlon Lifescience Private Limited	AAPCA0663H	Promoter Group	Trade Payable	KMP Interested	-	-	-	177.01	-	-	-	-	-	-	-	-
5	Anlon Healthcare Limited	AAMCA1673J	Meet Atulkumar Vachhani	ACWPV0197P	WHOLE TIME DIRECTOR	Remuneration Paid	KMP Interested	5.73	5.73	-	-	-	-	-	-	-	-	-	-
6	Anlon Healthcare Limited	AAMCA1673J	Punitkumar Rameshbhai Rasadia	AJPPR6932E	MANAGING DIRECTOR	Remuneration Paid	KMP Interested	17.16	17.16	-	-	-	-	-	-	-	-	-	-

For and on behalf of the Board of Anlon Healthcare Limited

  
**Punitkumar R. Rasadia**  
 Managing Director

Date: 11-11-2025  
 Place: Rajkot

